AKRO
Price
$50.56
Change
+$0.05 (+0.10%)
Updated
Jul 25 closing price
Capitalization
4.03B
12 days until earnings call
SLS
Price
$1.80
Change
-$0.03 (-1.64%)
Updated
Jul 25 closing price
Capitalization
179.6M
11 days until earnings call
Interact to see
Advertisement

AKRO vs SLS

Header iconAKRO vs SLS Comparison
Open Charts AKRO vs SLSBanner chart's image
Akero Therapeutics
Price$50.56
Change+$0.05 (+0.10%)
Volume$561.89K
Capitalization4.03B
SELLAS Life Sciences Group
Price$1.80
Change-$0.03 (-1.64%)
Volume$1.01M
Capitalization179.6M
AKRO vs SLS Comparison Chart in %
Loading...
AKRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AKRO vs. SLS commentary
Jul 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKRO is a Hold and SLS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 27, 2025
Stock price -- (AKRO: $50.56 vs. SLS: $1.80)
Brand notoriety: AKRO and SLS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKRO: 39% vs. SLS: 32%
Market capitalization -- AKRO: $4.03B vs. SLS: $179.6M
AKRO [@Biotechnology] is valued at $4.03B. SLS’s [@Biotechnology] market capitalization is $179.6M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKRO’s FA Score shows that 0 FA rating(s) are green whileSLS’s FA Score has 0 green FA rating(s).

  • AKRO’s FA Score: 0 green, 5 red.
  • SLS’s FA Score: 0 green, 5 red.
According to our system of comparison, AKRO is a better buy in the long-term than SLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKRO’s TA Score shows that 4 TA indicator(s) are bullish while SLS’s TA Score has 4 bullish TA indicator(s).

  • AKRO’s TA Score: 4 bullish, 5 bearish.
  • SLS’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both AKRO and SLS are a bad buy in the short-term.

Price Growth

AKRO (@Biotechnology) experienced а -2.92% price change this week, while SLS (@Biotechnology) price change was +1.69% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.62%. For the same industry, the average monthly price growth was +17.39%, and the average quarterly price growth was +28.36%.

Reported Earning Dates

AKRO is expected to report earnings on Nov 12, 2025.

SLS is expected to report earnings on Nov 12, 2025.

Industries' Descriptions

@Biotechnology (+7.62% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AKRO($4.03B) has a higher market cap than SLS($180M). AKRO YTD gains are higher at: 81.740 vs. SLS (73.077). SLS has higher annual earnings (EBITDA): -27.93M vs. AKRO (-264.59M). AKRO has more cash in the bank: 686M vs. SLS (28.4M). SLS has less debt than AKRO: SLS (870K) vs AKRO (36.6M). AKRO (0) and SLS (0) have equivalent revenues.
AKROSLSAKRO / SLS
Capitalization4.03B180M2,239%
EBITDA-264.59M-27.93M947%
Gain YTD81.74073.077112%
P/E RatioN/AN/A-
Revenue00-
Total Cash686M28.4M2,415%
Total Debt36.6M870K4,207%
FUNDAMENTALS RATINGS
AKRO vs SLS: Fundamental Ratings
AKRO
SLS
OUTLOOK RATING
1..100
5956
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
55
Fair valued
PROFIT vs RISK RATING
1..100
58100
SMR RATING
1..100
9499
PRICE GROWTH RATING
1..100
3940
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AKRO's Valuation (39) in the null industry is in the same range as SLS (55) in the Biotechnology industry. This means that AKRO’s stock grew similarly to SLS’s over the last 12 months.

AKRO's Profit vs Risk Rating (58) in the null industry is somewhat better than the same rating for SLS (100) in the Biotechnology industry. This means that AKRO’s stock grew somewhat faster than SLS’s over the last 12 months.

AKRO's SMR Rating (94) in the null industry is in the same range as SLS (99) in the Biotechnology industry. This means that AKRO’s stock grew similarly to SLS’s over the last 12 months.

AKRO's Price Growth Rating (39) in the null industry is in the same range as SLS (40) in the Biotechnology industry. This means that AKRO’s stock grew similarly to SLS’s over the last 12 months.

AKRO's P/E Growth Rating (100) in the null industry is in the same range as SLS (100) in the Biotechnology industry. This means that AKRO’s stock grew similarly to SLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AKROSLS
RSI
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
81%
MACD
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 10 days ago
83%
Bullish Trend 24 days ago
86%
Declines
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 2 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
AKRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TTNDF11.97N/A
+0.01%
Techtronic Industries Ltd.
HLFN31.42N/A
N/A
Home Loan Financial Corp.
NGKSY16.52N/A
N/A
NITERRA CO LTD.
QRON0.07N/A
N/A
Qrons Inc.
FBAK260.00-5.00
-1.89%
First National Bank Alaska

SLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLS has been loosely correlated with FULC. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SLS jumps, then FULC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLS
1D Price
Change %
SLS100%
-1.64%
FULC - SLS
48%
Loosely correlated
-0.13%
NKTR - SLS
42%
Loosely correlated
+1.71%
AKRO - SLS
41%
Loosely correlated
+0.10%
TAOX - SLS
34%
Loosely correlated
-5.51%
AXON - SLS
32%
Poorly correlated
+3.63%
More